BioSpace News Archive

Health Canada approved Enhertu ™ (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience.

Adaptive Phage Therapeutics, Inc., today announced the first patient has been dosed in the PHAGE clinical trial, evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa ( P. aeruginosa ) in their lungs.

NLS Pharmaceutics Ltd. today announced that it received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq’s minimum bid price requirement.

IMUNON, Inc., a clinical-stage drug development company announced it has received $1.6 million in net cash proceeds from the sale of approximately $1.7 million of its unused New Jersey net operating losses.

Milestone Scientific Inc. today announced it has entered into a distribution agreement with Sweden & Martina , a leading European dental distributor and manufacturer.

Pixium Vision SA announces that the second generation of implants for its bionic vision system PRIMA for atrophic age-related macular degeneration could restore vision at five times higher resolution than the current PRIMA implants.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that a drug candidate has been nominated from the P003 research project.

Biophytis SA received a deficiency notice from The Nasdaq Stock Market, Inc. stating that the Company has not filed its financial information for the six-month period ended June 30, 2022 on a Form 6-K and as a result the Company no longer complies with Nasdaq’s listing rules for continued listing set forth in the Listing Rule 5250.

REVIVE THERAPEUTICS LTD. is pleased to announce that it has completed the closing of its previously announced private placement by issuing a total of 28,676,064 units, at a price of $0.15 per Unit, for gross proceeds of $4,301,409.